Laborie Medical Technologies Invests in iO Urology and the CarePath Uroflow Device

iO Urology

Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow device that is FDA-approved and has been utilized in multiple urology clinics in the U.S.

CarePath’s simplistic model allows the device to be shipped directly to the patient’s home and uses embedded cellular connectivity. This provides reliable, accurate data and improves diagnosing and managing lower urinary tract (LUTS) issues such as BPH (Benign Prostatic Hyperplasia). Patients see their voids and functions first-hand and receive education about BPH and the various treatment options available to manage the disease.

# of Patients in the US with BPH Symptoms

As many as 14 million men in the United States have symptoms of BPH, and if left untreated, BPH can lead to severe disease of the bladder and kidneys. A gap in patient awareness and education about BPH is believed to be the primary reason driving non-compliance and lack of engagement. Most patients seek specialist care from a urologist, and many leave with a prescription for oral therapy. However, just a fraction of patients return for a follow-up visit.

With CarePath, 91% of patients returned to the clinic to review the CarePath Uroflow report with their provider and consider surgical intervention. Men who were educated with repetitive measurements of urine volume flow and disease education were significantly more likely to engage in managing the condition.

Tim Panciera, Vice President and General Manager of Laborie’s Urology Business Unit

“At Laborie, we strongly believe in the value of patient education as a pathway to support the restoration of patient dignity. The team at iO Urology developed a state-of-the-art device with a dynamic patient ecosystem that empowers patient engagement as a superior standard of care. Our missions are closely aligned, making this a natural investment to continue accelerating Laborie’s position and expertise in the advanced diagnostics market.”

“We’re eager to collaborate with Laborie, pioneers in diagnostic and therapeutic urologic healthcare,” said iO Urology Co-Founder and CEO Britton Garrett. “CarePath bridges the clinic-patient gap, offering a convenient, accessible solution for managing urological conditions in the home.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version